The Society for Immunotherapy of Cancer Biomarkers Task Force Recommendations Review

Publication date: Available online 22 September 2017 Source:Seminars in Cancer Biology Author(s): Lisa H. Butterfield The clinical successes in cancer immunotherapy have led to a critical need for biomarkers in cancer immunotherapy. It is of the utmost importance to know who is most likely to benefit from these therapies (predictive biomarkers) but also who is starting to respond (prognostic biomarkers) and how the therapy functions in order to make rational combination choices (mechanism of action biomarkers). The Society for Immunotherapy of Cancer (SITC) Biomarkers Task Force addressed the state of the art and made a series of recommendations for the field, which is summarized here.
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research